Immobilized kidney 28-kda endostatin-related (KES28kDa) fragment promotes endothelial cell survival

American Journal of Nephrology

Volumn 31, Issue 3, 2010, Pages 255-261

  Bellini, Maria Helena ^a,b   Malpighi, Thiago França ^a   Calvo, Fernanda Bernardes ^a   Miranda, Adriana Regina ^a   Spencer, Patrick Jack ^a   Cichy, Milena Cristina ^b   Simons, Simone Michaela ^c   Chudzinski Tavassi, Ana Marisa ^c   Fagundes Dos Santos, Marinilce ^d   Junqueira Rodrigues, Consuelo ^d   Schor, Nestor ^b  

^a INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c INSTITUTO BUTANTAN   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acute kidney injury; Endostatin; Endothelial cell survival; Human umbilical vein endothelial cells; KES28kDa

Indexed keywords

28 KDA ENDOSTATIN; ENDOSTATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY ARTERY STENOSIS; KIDNEY FUNCTION; KIDNEY ISCHEMIA; KIDNEY VEIN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PURIFICATION; STRESS FIBER; UMBILICAL VEIN; VEIN OCCLUSION;

EID: 75149195928     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000278756     Document Type: Article

References (36)

1. Nangaku M, Eckardt KU: Hypoxia and the HIF system in kidney disease. J Mol Med 2007; 85: 1325-1330.
2. Liangos O, Wald R, O'Bell JW, Price L, Pereira BJ, Jaber BL: Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey. Clin J Am Soc Nephrol 2006; 1: 43-51.
3. Kaushal GP, Basnakian AG, Shah SV: Apoptotic pathways in ischemic acute renal failure. Kidney Int 2004; 66: 500-506.
4. Stahl PJ, Felsen D: Transforming growth factor-β, basement membrane, and epithelialmesenchymal transdifferentiation implications for fibrosis in kidney disease. Am J Pathol 2001; 159: 1187-1192.
5. Short M, Nemenoff RA, Zawada WM, Stenmark KR, Das M: hypoxia induces differentiation of pulmonary artery adventitial fibroblasts into myofibroblasts. Am J Physiol 2004; 286:C416-C425.
6. Yamamoto T, Tada T, Brodsky SV, Tanaka H, Noiri E, Kajiya F, Goligorsky MS: Intravital videomicroscopy of peritubular capillaries in renal ischemia. Am J Physiol Renal Physiol 2002; 282:F1150-F1155.
7. Brodsky SV, Yamamoto T, Tada T, Kim B, Chen J, Kajiya F, Goligorsky MS: Endothelial dysfunction in ischemic acute renal failure: rescue by transplanted endothelial cells. Am J Physiol Renal Physiol 2002; 282:F1140-F1149.
8. Sutton TA, Fisher CJ, Molitoris BA: Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int 2002; 62: 1539-1549.
9. Sutton TA, Mang HE, Campos SB, Sandoval RM, Yoder MC, Molitoris BA: Injury of the renal microvascular endothelium alters barrier function following ischemia. Am J Physiol Renal Physiol 2003; 285:F191-F198.
10. Okusa MD: The inflammatory cascade in acute ischemic renal failure. Nephron 2002; 90: 133-138.
11. Halfter W, Dong S, Schurer B, Cole GJ: Collagen XVIII is a basement membrane heparan sulfate proteoglycan. J Biol Chem 1998; 273: 25404-25412.
12. Sasaki T, Fukai N, Mann K, Göhring W, Olsen BR, Timpl R: Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J 1998; 17: 4249-4256.
13. Miosge N, Sasaki T, Timpl R: Angiogenesis inhibitor endostatin is a distinct component of elastic fibers in vessel walls. FASEB J 1999; 13: 1743-1750.
14. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
15. Felbor U, Dreier L, Bryant RA, Ploegh HL, Olsen BR, Mothes W: Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 2000; 19: 1187-1194.
16. Lin HC, Chang JH, Jain S, Gabison EE, Kure T, Kato T, Fukai N, Azar DT: Matrilysin cleavage of corneal collagen type XVIII NC1 domain and generation of a 28-kDa fragment. Invest Ophthalmol Vis Sci 2001; 42: 2517-2524.
17. Rehn M, Veikkola T, Kukk-Valdre E, Nakamura H, Ilmonen M, Lombardo C, Pihlajaniemi T, Alitalo K, Vuori K: Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci USA 2001; 98: 1024-1029.
18. Li C, Harris MB, Venema VJ, Venema RC: Endostatin induces acute endothelial nitric oxide and prostacyclin release. Biochem Biophys Res Commun 2005; 329: 873-878.
19. Schmidt A, Wenzel D, Ferring I, Kazemi S, Sasaki T, Hescheler J, Timpl R, Addicks K, Fleischmann BK, Bloch W: Influence of endostatin on embryonic vasculo- and angiogenesis. Dev Dyn 2004; 230: 468-480.
20. Miner JH: Renal basement membrane components. Kidney Int 1999; 56: 2016-2024.
21. Tomono Y, Naito I, Ando K, Yonezawa T, Sado Y, Hirakawa S, Arata J, Okigaki T, Ninomiya Y: Epitope-defined monoclonal antibodies against multiplexin collagens demonstrate that type XV and XVIII collagens are expressed in specialized basement membranes. Cell Struct Funct 2002; 27: 9-20.
22. Maciel TT, Coutinho EL, Soares D, Achar E, Schor N, Bellini MH: Endostatin, an antiangiogenic protein, is expressed in the unilateral ureteral obstruction mice model. J Nephrol 2008; 21: 753-760.
23. Bellini MH, Coutinho EL, Filgueiras TC, Maciel TT, Schor N: Endostatin expression in the murine model of ischaemia/reperfusion- induced acute renal failure. Nephrology (Carlton) 2007; 12: 459-465.
24. Conger JD, Weil JV: Abnormal vascular function following ischemia-reperfusion injury. J Investig Med 1995; 43: 431-442.
25. Molitoris BA: Cellular basis of ischemic acute renal failure; in Lazarus JM, Brenner BN (eds): Acute Renal Failure. New York, Churchill Livingstone, 1993, pp 1-32.
26. Hefler L, Tempfer C, Kainz C, Obermair A: Serum concentrations of endostatin in patients with vulvar cancer. Gynecol Oncol 1999; 74: 151-152.
27. Bertolini F, Paolucci M, Peccatori F, Cinieri S, Agazzi A, Ferrucci PF, Cocorocchio E, Goldhirsch A, Martinelli G: Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol 1999; 106: 504-509.
28. Yamagata M, Shiratori Y, Dan Y, Shiina S, Takayama T, Makuuchi M, Omata M: Serum endostatin levels in patients with hepatocellular carcinoma. Ann Oncol 2000; 11: 761-762.
29. Feldman AL, Tamarkin L, Paciotti GF, Simpson BW, Linehan WM, Yang JC, Fogler WE, Turner EM, Alexander HR Jr, Libutti SK: Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res 2000; 6: 4628-4634.
30. Morimoto T, Aoyagi M, Tamaki M, Yoshino Y, Hori H, Duan L, Yano T, Shibata M, Ohno K, Hirakawa K, Yamaguchi N: Increased levels of tissue endostatin in human malignant gliomas. Clin Cancer Res 2002; 8: 2933-2938.
31. Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaissé J: Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 2000; 486: 247-251.
32. Yamaguchi N, Anand-Apte B, Lee M, Sasaki T, Fukai N, Shapiro R, Que I, Lowik C, Timpl R, Olsen BR: Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 1999; 18: 4414-4423.
33. Faye C, Moreau C, Chautard E, Jetne R, Fukai N, Ruggiero F, Humphries JM, Olsen RB, Blum SR: Molecular interplay between endostatin, integrins, and heparan sulfate. J Biol Chem 2009; 284: 22029-22040.
34. Wickström SA, Alitalo K, Keski-Oja J: Endostatin associates with lipid rafts and induces reorganization of the actin cytoskeleton via down-regulation of RhoA activity. J Biol Chem 2003; 278: 37895-37901.
35. Wickström SA, Alitalo K, Keski-Oja J: Endostatin associates with integrin α5β1 and caveolin- 1, and activates Src via a tyrosyl phosphatase- dependent pathway in human endothelial cells. Cancer Res 2002; 62: 5580-5589.
36. Wickström SA, Alitalo K, Keski-Oja J: An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells. J Biol Chem 2004; 279: 20178-20185.